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NEW FINDINGS 72 
• LVAD patients are predisposed to hypertension which may increase the risk of stroke.  73 
Hypertension may result from markedly elevated levels of sympathetic nerve activity, 74 
which occurs through a baroreceptor-mediated pathway in response to chronic exposure 75 
to a non-physiologic (and reduced) pulse.	76 
• Cerebral autoregulatory processes appear to be preserved in the absence of a 77 
physiologic pulse.  Nevertheless, the rate of ischemic/embolic and hemorrhagic stroke is 78 
unacceptably high and is a major cause of morbidity and mortality in these patients.	79 
• Despite normalization of a resting cardiac output, LVAD patients suffer from persistent, 80 
severe reductions in functional capacity, with a peak oxygen consumption (VO2) that is 81 
















ABSTRACT  96 
 Current generation left ventricular assist devices (LVADs) have led to significant 97 
improvements in survival compared to medical therapy alone, when used for management 98 
of patients with advanced heart failure.  However, there are a number of side-effects 99 
associated with LVAD use, including hypertension, gastrointestinal bleeding, stroke, as well 100 
as persistent and severe limitations in functional capacity despite normalization of a resting 101 
cardiac output (Qc).  These issues are, in large part, related to chronic exposure to a non-102 
physiologic pulse, which contributes to a hyperadrenergic environment characterized by 103 
markedly elevated levels of sympathetic nerve activity through a baroreceptor-mediated 104 
pathway.  In addition, these machines are unable to participate in, or contribute to, normal 105 
cardiovascular/autonomic reflexes that attempt to modulate flow through the body.  Efforts 106 
to advance device technology and develop biologically sensitive devices may resolve these 107 
issues, and lead to further improvements in quality-of-life, functional capacity, and 108 














Normal bodily processes that regulate resting and exertional blood pressure and 121 
systemic perfusion are well-described among healthy individuals.  However, among 122 
individuals suffering from heart failure with reduced ejection fraction (HFrEF), 123 
cardiopulmonary abnormalities including impaired contractile reserve, endothelial 124 
dysfunction, and a host of musculoskeletal abnormalities, act simultaneously to limit 125 
functional capacity, quality-of-life (QOL), and overall survival.  While compensatory 126 
mechanisms, such as heightened sympathetic nerve activity (SNA), maintain arterial 127 
perfusion pressure by increasing total peripheral resistance, as HFrEF progresses, these 128 
mechanisms become counterproductive and actually contribute to impairments in functional 129 
capacity and survival.(J. N. Cohn et al., 1984)   130 
Heart transplantation is the gold-standard management strategy for individuals with 131 
advanced, end-stage HFrEF.  However, the demand for suitable donor organs far outweighs 132 
the supply, and further, medical or socioeconomic factors may preclude transplantation 133 
among HFrEF patients.  As such, there has been a rapid increase in the use of left 134 
ventricular assist devices (LVADs) for temporary or permanent management of HFrEF.  135 
These devices markedly improve survival and QOL and have favorably altered the 136 
landscape of advanced HF management (Rogers et al., 2010). However, there are many 137 
risks associated with LVAD use, such as hypertension, stroke, an acquired von Willebrand 138 
syndrome and gastrointestinal bleeding.(W.K. Cornwell III et al., 2019; William K Cornwell III 139 
et al., 2014; Cornwell et al., 2015; Estep et al., 2015).  Further, functional capacity is 140 
severely limited (despite subjective measures of improved QOL).  As will be discussed, 141 
many of the complications related to LVADs among HFrEF patients result from two unique 142 
features associated with these devices: first, these devices provide continuous-flow (CF) 143 
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circulatory support, meaning that these patients have a non-physiologic and markedly 144 
reduced arterial pulse pressure compared to normal humans.  Further, LVADs are 145 
denervated machines with no biofeedback loop, and as such, they do not participate in 146 
normal cardiovascular, autonomic or exercise presser reflexes.   147 
EFFECT OF MECHANICAL CIRCULATORY SUPPORT ON BLOOD PRESSURE 148 
Blood pressure (BP) is regulated on a beat-to-beat basis by the arterial baroreceptor 149 
reflex pathway, as well as sympathoadrenal and renin-angiotensin axes.  Studies on 150 
animals (Chapleau & Abboud, 1987; Chapleau, Hajduczok, & Abboud, 1989) and humans 151 
(Cornwell et al., 2015) suggest that rhythmic pulsatile distension of the baroreceptors, 152 
throughout the cardiac cycle, regulates SNA, such that expansion of the receptors during 153 
systole reduces sympathetic tone, and that recoiling of the receptors during diastole, or in 154 
instances of dehydration or hypotension, leads to an increase in sympathetic tone.   155 
It is well known that HFrEF patients have elevated levels of SNA (Barretto et al., 156 
2009) and circulating catecholamines (J.N. Cohn et al., 1984), the degree of which 157 
increases in proportion to HF severity (J.N. Cohn et al., 1984). This hyperadrenergic 158 
environment leads to an increase in total peripheral resistance to ensure that mean arterial 159 
pressure (MAP) is maintained despite the reduced cardiac output (Qc) that is characteristic 160 
of HFrEF. However, this increase in adrenergic tonicity initiates a vicious cycle, whereby the 161 
increase in left ventricular afterload further compromises Qc, which in turn, leads to greater 162 
increases in adrenergic signaling.  Thus, sympathetic tone is extraordinarily high among the 163 
cohort of HFrEF patients who qualify for LVAD implantation. 164 
Longitudinal studies assessing changes in sympathetic tone prior to – and following – 165 
LVAD implantation among individuals with HFrEF, have not been performed.  However, 166 
LVAD patients are known to have markedly elevated levels of muscle SNA (MSNA), a 167 
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phenomenon which is mediated, at least in part, by a baroreceptor-mediated pathway 168 
resulting from diminished pulsatility (Cornwell et al., 2015). In addition, since flow through 169 
the LVAD is continuous, diastolic blood pressure is elevated, which increases MAP and 170 
predisposes to overt hypertension (W.K. Cornwell III et al., 2019). For this reason, LVAD 171 
patients frequently require multiple classes of antihypertensive medications.  172 
IMPLICATIONS OF CONTINUOUS-FLOW CIRCULATORY SUPPORT ON 173 
CEREBROVASCULAR PHYSIOLOGY  174 
 The predilection for hypertension among LVAD patients likely contributes to the 175 
increased stroke risk.  Strokes traditionally affect 10% of patients in the first year of support 176 
alone, and between 6-24 months, are the primary cause of death (W.K. Cornwell III et al., 177 
2019). Animal models suggest that hypertension causes a rightward shift in the cerebral 178 
autoregulatory curve (by as much as 50mmHg at the upper end and 30mmHg at the lower 179 
end of the curve,(W.K. Cornwell III et al., 2019; Faraci FM, Baumbach GL, & DD., 1990; 180 
Harper & Bohlen, 1984)). Further, hypertension reduces maximal vasodilatory capacity of 181 
cerebral arterioles due to vessel hypertrophy and increased cerebrovascular resistance, 182 
which may blunt changes in cerebral blood flow (CBF) that would otherwise occur in 183 
response to modulations in perfusion pressure (Faraci FM et al., 1990; Johansson & 184 
Nilsson, 1979; Sadoshima S, Bisija D.W., & Heistad, 1983). 185 
 HFrEF patients have a downward shift in the autoregulatory curve (Caldas et al., 186 
2017). Longitudinal studies comparing changes in autoregulatory curves among HFrEF 187 
patients prior to, and following LVAD implantation have not been performed.  However, 188 
cerebral autoregulation among LVAD patients is preserved – at least among those with 189 
normal blood pressure (William K Cornwell III et al., 2014), suggesting that the curve may 190 
be upward shifted and normalized/improved in these patients (W.K. Cornwell III et al., 191 
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2019). In addition, there is indirect evidence to suggest that the increased sympathetic tone 192 
may play somewhat of a protective role for these patients, since at least in feline models, 193 
stimulation of the sympathetic nervous system attenuated increases in CBF and disruption 194 
of the blood brain barrier, that otherwise would have occurred in response to acute rises in 195 
BP (Busija, Heistad, & Marcus, 1980; Heistad & Marcus, 1979). 196 
EXERCISE CAPACITY IN THE SETTING OF MECHANICAL CIRCULATORY SUPPORT 197 
 At the time of CF-LVAD implantation, patients generally have a peak oxygen uptake 198 
(VO2) of 12-14ml/kg/min or less, consistent with a severe reduction in functional capacity.  199 
The New York Heart Association functional classification – a subjective assessment of 200 
function, improves dramatically following device implantation (Rogers et al., 2010). Further, 201 
submaximal exercise performance, as determined by six-minute hall walk, increases 202 
modestly after recovery from device implantation (Rogers et al., 2010). However, peak VO2 203 
typically does not improve following device implantation and remains severely reduced, 204 
typically less than 15ml/kg/min more than one year following LVAD insertion (Jung & 205 
Gustafsson, 2015; Mette Holme Jung et al., 2014). There are many potential explanations 206 
for this persistent reduction in functional capacity. First, it is important to emphasize that 207 
LVADs normalize resting cardiac output, not cardiac output during exercise.  Pump speed 208 
adjustment studies during exercise suggest that the LVAD has a limited ability to augment 209 
flow, which suggests that the cardiac output during exercise depends on contractile reserve 210 
of the native left ventricle as opposed to the device itself (Brassard et al., 2011; M. H. Jung 211 
et al., 2014; Noor, Bowles, & Banner, 2012). Second, exercise among HFrEF patients is 212 
limited by pulmonary, peripheral vascular, and musculoskeletal factors, in addition to left 213 
ventricular systolic dysfunction, and it is not clear that LVAD implantation improves extra-214 
cardiac systems that are perturbed in the setting of HFrEF. Finally, the exercise presser 215 
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reflex in HFrEF is markedly abnormal and characterized by hyperactive group III afferents 216 
(mechanoreceptors, (Middlekauff & Sinoway, 2007)), and there are no data to suggest that 217 
this level of mechanoreceptor hyperactivity improves following device implantation.   218 
FUTURE DIRECTIONS 219 
Technologic refinements of current-generation LVADs are geared towards creation of 220 
biologically sensitive, fully implantable – and ultimately, “forgettable” pumps for the patients 221 
they support.  To achieve this goal, there is interest in restoring pulsatility, possibly through 222 
automated modulations in pump speed.  For example, the Heartmate 3 LVAD, one type of 223 
commercially available pump, automatically increases and decreases pump speed at a 224 
frequency of 0.5Hz to wash the pump bearings and minimize thrombus formation.  It is 225 
possible that these speed changes induce some degree of pulsatile flow in the body, but it is 226 
unknown at this time whether this engineering characteristic actually provides a physiologic 227 
pulse.  In addition, there is great interest in developing devices that increase flow during 228 
exercise (similar to the normal heart) and improve functional capacity.  However, current-229 
generation devices are denervated and do not participate in autonomic/cardiovascular 230 
reflexes and ultimately, are insensitive to the body’s attempt to exercise.  Pacemakers, 231 
implanted into individuals with conduction disease, frequently incorporate accelerometers 232 
and/or ventilator sensors that augment Qc in response to acceleration or an increase in 233 
breathing frequency (ie, behaviors characteristic of exercise).  Whether incorporation of 234 
similar technology into LVAD design and function would improve LVAD flow during activity is 235 
unknown.  A great deal of research is warranted in this area.   236 
CONCLUSION 237 
 Advancements in LVAD technology have led to marked improvements in survival for 238 
patients with advanced HFrEF.  However, there are a number of comorbidities that affect 239 
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these patients, and limit them from enjoying a higher QOL.  Physiologically, the primary 240 
issues that interfere with normal bodily processes include a non-physiologic pulse, and the 241 
inability of these devices to participate in, or respond to cardiovascular/autonomic reflexes.  242 
It is foreseeable that continued improvements in device design and technology will resolve 243 
these issues, and lead to implementation of more biologically compatible pumps that further 244 
improve QOL, functional capacity, and ultimately, survival.  245 
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